Factors Associated with Late Local Radiation Toxicity after Post-Operative Breast Irradiation

M C T Batenburg, M Bartels, W Maarse, A Witkamp, H M Verkooijen, H J G D van den Bongard, M C T Batenburg, M Bartels, W Maarse, A Witkamp, H M Verkooijen, H J G D van den Bongard

Abstract

Purpose: To assess determinants associated with late local radiation toxicity in patients treated for breast cancer.

Methods: A systematic review was performed. All studies reporting ≥2 variables associated with late local radiation toxicity after treatment with postoperative whole breast irradiation were included. Cohort studies, randomized controlled trials, and cross-sectional studies were eligible designs. Study characteristics and definitions of determinants and outcome measures were extracted. If possible, the measure of association was extracted.

Results: Twenty-one studies were included in this review. Six out of seven studies focused on the association between radiotherapy (boost) dose or irradiated breast volume and late radiation toxicity found significant results. Tumor bed boost was associated with late radiation toxicity, fibrosis, and/or edema in six out of twelve studies. Lower age was associated with late breast toxicity in one study, while in another study, higher age was significantly associated with breast fibrosis. Also, no association between age and late radiation toxicity was found in eight out of twelve studies. Similar inconsistent results were found in the association between late radiation toxicity and other patient-related factors (i.e., breast size, diabetes mellitus) and surgical and systemic treatment-related factors (i.e., complications after surgery, chemotherapy, and time between surgery and radiotherapy).

Conclusion: In modern 3D radiotherapy, radiotherapy (boost) dose and volume are-like in 2D radiotherapy-associated with late local radiation toxicity, such as breast fibrosis and edema. Treatment de-escalation, for example, partial breast irradiation in selected patients might be important to decrease late local toxicity without compromising locoregional control and survival.

Conflict of interest statement

The authors have no conflicts of interest to declare.

Copyright © 2022 M.C.T. Batenburg et al.

Figures

Figure 1
Figure 1
Flowchart of selected studies to evaluate which determinants were associated with late radiation toxicity in breast cancer patients.
Figure 2
Figure 2
Risk of bias assessment for included studies using the quality in prognostic Studies (QUIPS) tool.

References

    1. Netherlands Cancer Registry. Cijfers over kanker. 2020. .
    1. Runowicz C. D., Leach C. R., Henry N. L., et al. American cancer society/American society of clinical oncology breast cancer survivorship care guideline. Journal of Clinical Oncology . 2016;34(6):611–635. doi: 10.1200/jco.2015.64.3809.
    1. Fallowfield L., Jenkins V. Psychosocial/survivorship issues in breast cancer: are we doing better? Journal of the National Cancer Institute . 2015;107(1):p. 335.
    1. Curran D., van Dongen J. P., Aaronson N. K., et al. Quality of life of early-stage breast cancer patients treated with radical mastectomy or breast-conserving procedures: results of EORTC trial 10801. European Journal of Cancer . 1998;34(3):307–314. doi: 10.1016/s0959-8049(97)00312-2.
    1. Mukesh M., Harris E., Jena R., Evans P., Coles C. Relationship between irradiated breast volume and late normal tissue complications: a systematic review. Radiotherapy and Oncology . 2012;104(1):1–10. doi: 10.1016/j.radonc.2012.04.025.
    1. Yee C., Wang K., Asthana R., et al. Radiation-induced skin toxicity in breast cancer patients: a systematic review of randomized trials. Clinical Breast Cancer . 2018;18(5):e825–e840. doi: 10.1016/j.clbc.2018.06.015.
    1. De Felice F., Ranalli T., Musio D., et al. Relation between hypofractionated radiotherapy, toxicity and outcome in early breast cancer. Breast Journal . 2017;23(5):563–568. doi: 10.1111/tbj.12792.
    1. Collette S., Collette L., Budiharto T., et al. Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer—a study based on the EORTC trial 22881-10882 “boost versus no boost”. European Journal of Cancer . 2008;44(17):2587–2599. doi: 10.1016/j.ejca.2008.07.032.
    1. Whelan T. J., Pignol J.-P., Levine M. N., et al. Long-term results of hypofractionated radiation therapy for breast cancer. New England Journal of Medicine . 2010;362(6):513–520. doi: 10.1056/nejmoa0906260.
    1. Haviland J. S., Owen J. R., Dewar J. A., et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncology . 2013;14(11):1086–1094. doi: 10.1016/s1470-2045(13)70386-3.
    1. Murray Brunt A., Haviland J. S., Wheatley D. A., et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet . 2020;395(10237):1613–1626. doi: 10.1016/s0140-6736(20)30932-6.
    1. Hamilton D. G., Bale R., Jones C., et al. Impact of tumour bed boost integration on acute and late toxicity in patients with breast cancer: a systematic review. Breast . 2016;27:126–135. doi: 10.1016/j.breast.2016.03.002.
    1. Offersen B. V., Alsner J., Nielsen H. M., et al. Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase III trial: the DBCG HYPO trial. Journal of Clinical Oncology . 2020;38(31):3615–3625. doi: 10.1200/jco.20.01363.
    1. Keramati A., Javadinia S. A., Gholamhosseinian H., Fanipakdel A., Homaei Shandiz F., Taghizadeh-Hesary F. A review of intraoperative radiotherapy after neoadjuvant chemotherapy in patients with locally advanced breast cancer: from bench to bedside. Indian Journal of Gynecologic Oncology . 2020;18(110) doi: 10.1007/s40944-020-00465-w.
    1. Kashi A. S. Y., Karimi M., Rakhsha A., Javadzadegan A., Taghizadeh-Hesary F. The troponin-I release in patients with left-sided early-stage breast cancer undergoing adjuvant whole breast radiotherapy: an Iranian experience. International Journal of Cancer Management . 2020;13(10) doi: 10.5812/ijcm.107043.e107043
    1. Moher D., Liberati A., Tetzlaff J., et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine . 2009;6(7) doi: 10.1371/journal.pmed.1000097.e1000097
    1. Mukesh M. B., Barnett G. C., Wilkinson J. S., et al. Randomized controlled trial of intensity-modulated radiotherapy for early breast cancer: 5-year results confirm superior overall cosmesis. Journal of Clinical Oncology . 2013;31(36):4488–4495. doi: 10.1200/jco.2013.49.7842.
    1. Meattini I., Marrazzo L., Saieva C., et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-florence trial. Journal of Clinical Oncology . 2020;38(35):4175–4183. doi: 10.1200/jco.20.00650.
    1. Meattini I., Saieva C., Miccinesi G., et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. European Journal of Cancer . 2017;76:17–26. doi: 10.1016/j.ejca.2017.01.023.
    1. Hayden J. A., van der Windt D. A., Cartwright J. L., Côté P., Bombardier C. Assessing bias in studies of prognostic factors. Annals of Internal Medicine . 2013;158(4):280–286. doi: 10.7326/0003-4819-158-4-201302190-00009.
    1. Bronsart E., Dureau S., Xu H. P., et al. Whole breast radiotherapy in the lateral isocentric lateral decubitus position: long-term efficacy and toxicity results. Radiotherapy and Oncology . 2017;124(2):214–219. doi: 10.1016/j.radonc.2017.07.001.
    1. Barnett G. C., Wilkinson J. S., Moody A. M., et al. The Cambridge Breast Intensity-modulated Radiotherapy Trial: patient- and treatment-related factors that influence late toxicity. Clinical Oncology . 2011;23(10):662–673. doi: 10.1016/j.clon.2011.04.011.
    1. Lilla C., Ambrosone C. B., Kropp S., et al. Predictive factors for late normal tissue complications following radiotherapy for breast cancer. Breast Cancer Research and Treatment . 2007;106(1):143–150. doi: 10.1007/s10549-006-9480-9.
    1. Meattini I., Poortmans P., Kirova Y., et al. Hypofractionated whole breast irradiation after conservative surgery for patients aged less than 60 years: a multi-centre comparative study. Acta Oncologica . 2020;59(2):188–195. doi: 10.1080/0284186x.2019.1695061.
    1. Palumbo I., Mariucci C., Falcinelli L., et al. Hypofractionated whole breast radiotherapy with or without hypofractionated boost in early stage breast cancer patients: a mono-institutional analysis of skin and subcutaneous toxicity. Breast Cancer . 2019;26(3):290–304. doi: 10.1007/s12282-018-0923-z.
    1. La Rocca E., Meneghini E., Dispinzieri M., et al. Hypofractionated irradiation in 794 elderly breast cancer patients: an observational study. Breast Journal . 2020;26(2):188–196. doi: 10.1111/tbj.13489.
    1. Hosni A., Murray L., Barry A., et al. Prospective evaluation of weekly concomitant tumor bed boost with three-week hypofractionated whole breast irradiation in early breast cancer. Journal of Radiation Oncology . 2017;6(1):93–99. doi: 10.1007/s13566-017-0292-9.
    1. Lazzari G., Terlizzi A., Della Vittoria Scarpati G., et al. Predictive parameters in hypofractionated whole-breast 3D conformal radiotherapy according to the Ontario Canadian trial. OncoTargets and Therapy . 2017;10:1835–1842. doi: 10.2147/ott.s127833.
    1. Yu E., Huang D., Leonard K., DiPetrillo T., Wazer D., Hepel J. Analysis of outcomes using hypofractionated tumor bed boost combined with hypofractionated whole breast irradiation for early-stage breast cancer. Clinical Breast Cancer . 2017;17(8):638–643. doi: 10.1016/j.clbc.2017.05.010.
    1. De Rose F., Fogliata A., Franceschini D., et al. Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical results. Radiation Oncology . 2016;11(1):p. 120. doi: 10.1186/s13014-016-0701-z.
    1. Hannan R., Thompson R. F., Chen Y., Bernstein K., Kabarriti R., Skinner W. Chen C. C., Landau E., Miller E., Spierer M., Hong L., Kalnicki S. “Hypofractionated whole -breast radiation therapy: does breast size matter? International Journal of Radiation Oncology, Biology, Physics . 2012;84(3):894–901. doi: 10.1016/j.ijrobp.2012.01.093.
    1. De Rose F., Fogliata A., Franceschini D., et al. Hypofractionated whole breast irradiation and simultaneous integrated boost in large-breasted patients: long-term toxicity and cosmesis. Clinical Breast Cancer . 2020;20(6):527–533. doi: 10.1016/j.clbc.2020.06.005.
    1. Bergom C., Kelly T., Morrow N., et al. Prone whole-breast irradiation using three-dimensional conformal radiotherapy in women undergoing breast conservation for early disease yields high rates of excellent to good cosmetic outcomes in patients with large and/or pendulous breasts. International Journal of Radiation Oncology, Biology, Physics . 2012;83(3):821–828. doi: 10.1016/j.ijrobp.2011.08.020.
    1. Joseph K., Vos L. J., Gabos Z., et al. Skin toxicity in early breast cancer patients treated with field-in-field breast intensity-modulated radiotherapy versus helical inverse breast intensity-modulated radiotherapy: results of a phase III randomised controlled trial. Clinical Oncology . 2020;33(1):30–39. doi: 10.1016/j.clon.2020.07.005.
    1. Ciammella P., Podgornii A., Galeandro M., et al. Toxicity and cosmetic outcome of hypofractionated whole-breast radiotherapy: predictive clinical and dosimetric factors. Radiation Oncology . 2014;9(1):p. 97. doi: 10.1186/1748-717x-9-97.
    1. De Santis M. C., Bonfantini F., Di Salvo F., et al. Factors influencing acute and late toxicity in the era of adjuvant hypofractionated breast radiotherapy. Breast . 2016;29:90–95. doi: 10.1016/j.breast.2016.07.013.
    1. Digesù C., Deodato F., Macchia G., et al. Hypofractionated radiotherapy after conservative surgery may increase low–intermediate grade late fibrosis in breast cancer patients. Breast Cancer . 2018;10:143–151.
    1. Hille-Betz U., Vaske B., Bremer M., et al. Late radiation side effects, cosmetic outcomes and pain in breast cancer patients after breast-conserving surgery and three-dimensional conformal radiotherapy. Strahlentherapie und Onkologie . 2016;192(1):8–16. doi: 10.1007/s00066-015-0899-y.
    1. Ishiyama H., Niino K., Hosoya T., Hayakawa K. Results of a questionnaire survey for symptom of late complications caused by radiotherapy in breast conserving therapy. Breast Cancer . 2006;13(2):197–201. doi: 10.2325/jbcs.13.197.
    1. Kelemen G., Varga Z., Lázár G., Thurzó L., Kahán Z. Cosmetic outcome 1-5 years after breast conservative surgery, irradiation and systemic therapy. Pathology and Oncology Research . 2012;18(2):421–427. doi: 10.1007/s12253-011-9462-z.
    1. Keller L. M. M., Sopka D. M., Li T., et al. Five-year results of whole breast intensity modulated radiation therapy for the treatment of early stage breast cancer: the Fox Chase Cancer Center experience. International Journal of Radiation Oncology, Biology, Physics . 2012;84(4):881–887. doi: 10.1016/j.ijrobp.2012.01.069.
    1. U.S. Department of Health and Human Services. Common Terminology Criteria of Adverse Events (CTCAE) Washington, DC, USA: U.S. Department of Health and Human Services; 2010.
    1. Cox J. D., Stetz J., Pajak T. F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC) International Journal of Radiation Oncology, Biology, Physics . 1995;31(5):1341–1346. doi: 10.1016/0360-3016(95)00060-c.
    1. Pavy J.-J., Denekamp J., Letschert J., et al. Late effects toxicity scoring: the SOMA scale. Radiotherapy and Oncology . 1995;35(1):11–15. doi: 10.1016/0167-8140(95)97448-m.
    1. START Trialists’ Group, Bentzen S. M., Agrawal R. K., et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet . 2008;371(9618):1098–1107.
    1. Bane A. L., Whelan T. J., Pond G. R., et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology . 2014;25(5):992–998. doi: 10.1093/annonc/mdu090.
    1. START Trialists’ Group, Bentzen S. M., Agrawal R. K., et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology . 2008;9(4):331–341.
    1. Brunt A. M., Wheatley D., Yarnold J., et al. Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Radiotherapy and Oncology . 2016;120(1):114–118. doi: 10.1016/j.radonc.2016.02.027.
    1. Bhattacharya I. S., Haviland J. S., Kirby A. M., et al. Patient-reported outcomes over 5 Years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial. Journal of Clinical Oncology . 2019;37(4):305–317. doi: 10.1200/jco.18.00982.
    1. Coles C. E., Griffin C. L., Kirby A. M., et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet . 2017;390(10099):1048–1060. doi: 10.1016/s0140-6736(17)31145-5.
    1. Livi L., Meattini I., Marrazzo L., et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. European Journal of Cancer . 2015;51(4):451–463. doi: 10.1016/j.ejca.2014.12.013.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する